Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
VNDAthis companyVanda Pharmaceuticals Inc.	$4.01	-2.36×	1.59×	2.41×	-3.53×	-130.5%	94.0%	-70.0%	-102.0%	-67.4%	-43.3%	-21.2%	0.04×	0.57×	0×	2.39×	0.0%	2	-1.81	2	C
ACHVAchieve Life Sciences, Inc.	$6.55	-3.98×	10.07×	0×	-3.93×	-98.2%	0.0%	0.0%	0.0%	-254.0%	-150.5%	-22.8%	0.69×	0.11×	-67.01×	4.39×	0.0%	2	-2.57	2	C
ALLOAllogene Therapeutics, Inc.	$1.02	-1.57×	1.03×	0×	-1.88×	-114.2%	0.0%	0.0%	0.0%	-65.3%	-52.8%	-49.5%	0.28×	-0.18×	-192.5×	7.93×	0.0%	4	-3.65	2	C
ARCTArcturus Therapeutics Holdings Inc.	$10.42	-2.55×	0.78×	2.5×	0.61×	-144.1%	95.5%	-111.5%	-97.9%	-30.7%	-31.4%	-44.2%	0.12×	3.28×	0×	6.64×	0.0%	1	-0.72	2	C
AVIRAtea Pharmaceuticals, Inc.	$4.40	-1.84×	1.06×	0×	-1.19×	-75.3%	0.0%	0.0%	0.0%	-57.5%	-63.0%	-45.4%	0×	0.58×	0×	7.82×	0.0%	2	1.99	3	B-
CAPRCapricor Therapeutics, Inc.	$9.10	-12.77×	4.39×	0×	-10.7×	-20.2%	0.0%	0.0%	0.0%	-34.4%	-33.4%	-5.4%	0.06×	2.7×	-35.51×	9.01×	0.0%	2	0.16	2	C
Peer median	—	-2.55×	1.06×	0×	-1.88×	-98.2%	0.0%	0.0%	0.0%	-57.5%	-52.8%	-44.2%	0.12×	0.58×	-35.51×	7.82×	0.0%	2	-0.72	2	—